Sarecycline Truncal Acne Safety and Efficacy Response

Completed

Conditions studied: Acne Vulgaris

In brief

The purpose of this study is to determine the efficacy and safety of oral sarecycline 1.5 mg/kg/day in truncal acne. Patients with moderate to severe acne vulgaris will be observed over a period of 12 weeks. Lesion counts, investigator's global assessments, photography, and safety measures will be assessed for the trunk and face.

Key facts

Study ID

NCT05010538

Run by

Angela Moore

People needed

10

Starts

2021-03-09

Expected to finish

2021-08-31

Last updated by the study team

2023-08-01

Who can join

Age: 9 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female age 9 or above.
• Clinical diagnosis of moderate to severe truncal acne based on IGA

You may not qualify if…

• Known or suspected allergies or sensitivities to any components of the study drug.
• Any disorders that would preclude the use of tetracycline-class antibiotics or sarecycline.
• Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the trial results and/or put the subject at significant risk (according to the Investigator's judgment) if the subject takes part in the trial.
• Other protocol defined Inclusion/Exclusion criteria may apply.

Where it is running

• Arlington Research Center — Arlington, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.